TMEM230 and central nervous system cancer: To evaluate whether the changes in the cellular properties observed in U87 cell assays in which TMEM230 was downregulated, correlated with molecular pathways associated with patient glioma properties, differential gene expression analysis was performed from LGG subtypes and GBM tumors based on TMEM230 expression levels by comparing RNA-seq datasets.